Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
61.8.9329.3396
Address
Unit 4, 117 Broadway Nedlands, Western Australia (WA) 6009
Description
Argenica Therapeutics Ltd. provides neuroprotective treatment. It specializes in development and commercialization of a novel therapeutic known as ARG-007. It offers drug ARG-007 in multiple models of stroke and other central nervous system (CNS) injury models, specifically: stroke including non-human primates; traumatic brain injury; and perinatal hypoxia ischaemia. The company was founded on 20 November 2019 and is headquartered in Nedlands, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.29 - 0.99
Trade Value (12mth)
AU$27,064.00
1 week
-0.63%
1 month
-2.48%
YTD
49.52%
1 year
96.25%
All time high
1.02
EPS 3 yr Growth
274.50%
EBITDA Margin
N/A
Operating Cashflow
-$5m
Free Cash Flow Return
-46.80%
ROIC
-50.70%
Interest Coverage
N/A
Quick Ratio
6.70
Shares on Issue (Fully Dilluted)
105m
HALO Sector
Healthcare
Next Company Report Date
20-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
06 September 24 |
Positive DSMB Safety Outcome & Phase 2 Trial Progress Update
×
Positive DSMB Safety Outcome & Phase 2 Trial Progress Update |
28 August 24 |
Appendix 4E & Annual Report to 30 June 2024
×
Appendix 4E & Annual Report to 30 June 2024 |
28 August 24 |
Appendix 4G & Corporate Governance Statement
×
Appendix 4G & Corporate Governance Statement |
14 August 24 |
Results of Meeting
×
Results of Meeting |
14 August 24 |
Notification regarding unquoted securities - AGN
×
Notification regarding unquoted securities - AGN |
14 August 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
08 August 24 |
Application for quotation of securities - AGN
×
Application for quotation of securities - AGN |
08 August 24 |
Notification of cessation of securities - AGN
×
Notification of cessation of securities - AGN |
08 August 24 |
Cleansing Notice
×
Cleansing Notice |
08 August 24 |
Change of Director's Interest Notice x3
×
Change of Director's Interest Notice x3 |
31 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
24 July 24 |
Phase 2 Stroke Clinical Trial Update
×
Phase 2 Stroke Clinical Trial Update |
22 July 24 |
Investor Webinar Presentation
×
Investor Webinar Presentation |
15 July 24 |
Investor Presentation
×
Investor Presentation |
12 July 24 |
Notice of General Meeting/Proxy Form
×
Notice of General Meeting/Proxy Form |
09 July 24 |
Notice of initial substantial holder from IFL
×
Notice of initial substantial holder from IFL |
14 June 24 |
Application for quotation of securities - AGN
×
Application for quotation of securities - AGN |
14 June 24 |
Notification of cessation of securities - AGN
×
Notification of cessation of securities - AGN |
14 June 24 |
Cleansing Notice
×
Cleansing Notice |
12 June 24 |
Notification of cessation of securities - AGN
×
Notification of cessation of securities - AGN |
05 June 24 |
Application for quotation of securities - AGN
×
Application for quotation of securities - AGN |
05 June 24 |
Notification of cessation of securities - AGN
×
Notification of cessation of securities - AGN |
05 June 24 |
Cleansing Notice
×
Cleansing Notice |
05 June 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
05 June 24 |
Non-Executive Director Resignation
×
Non-Executive Director Resignation |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.